Alnylam Pharmaceuticals (ALNY) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $294.06 --0%
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
YRD, NNOX, BB, More
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
YRD, NNOX, BB, More
Join SI Premium – FREE
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
- Ennis (EBF) Reports In-Line Q1 EPS
- Blackberry earnings preview Q1: strong print expected, AI potential in focus
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
